806 related articles for article (PubMed ID: 10823831)
21. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation.
Berra E; Richard DE; Gothié E; Pouysségur J
FEBS Lett; 2001 Feb; 491(1-2):85-90. PubMed ID: 11226425
[TBL] [Abstract][Full Text] [Related]
22. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
[TBL] [Abstract][Full Text] [Related]
23. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
24. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
25. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
26. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
[TBL] [Abstract][Full Text] [Related]
27. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis.
Maxwell PH; Pugh CW; Ratcliffe PJ
Adv Exp Med Biol; 2001; 502():365-76. PubMed ID: 11950150
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
29. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
Stickle NH; Chung J; Klco JM; Hill RP; Kaelin WG; Ohh M
Mol Cell Biol; 2004 Apr; 24(8):3251-61. PubMed ID: 15060148
[TBL] [Abstract][Full Text] [Related]
30. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha.
Yuan Y; Hilliard G; Ferguson T; Millhorn DE
J Biol Chem; 2003 May; 278(18):15911-6. PubMed ID: 12606543
[TBL] [Abstract][Full Text] [Related]
31. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
32. The HIF pathway: implications for patterns of gene expression in cancer.
Wykoff CC; Pugh CW; Harris AL; Maxwell PH; Ratcliffe PJ
Novartis Found Symp; 2001; 240():212-25; discussion 225-31. PubMed ID: 11727931
[TBL] [Abstract][Full Text] [Related]
33. The von Hippel-Lindau tumor suppressor protein.
Ivan M; Kaelin WG
Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
[TBL] [Abstract][Full Text] [Related]
34. Regulation of the HIF pathway: enzymatic hydroxylation of a conserved prolyl residue in hypoxia-inducible factor alpha subunits governs capture by the pVHL E3 ubiquitin ligase complex.
Mole DR; Pugh CW; Ratcliffe PJ; Maxwell PH
Adv Enzyme Regul; 2002; 42():333-47. PubMed ID: 12123724
[No Abstract] [Full Text] [Related]
35. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.
Maynard MA; Qi H; Chung J; Lee EH; Kondo Y; Hara S; Conaway RC; Conaway JW; Ohh M
J Biol Chem; 2003 Mar; 278(13):11032-40. PubMed ID: 12538644
[TBL] [Abstract][Full Text] [Related]
36. p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1).
Schmid T; Zhou J; Köhl R; Brüne B
Biochem J; 2004 May; 380(Pt 1):289-95. PubMed ID: 14992692
[TBL] [Abstract][Full Text] [Related]
37. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.
Li Z; Na X; Wang D; Schoen SR; Messing EM; Wu G
J Biol Chem; 2002 Feb; 277(7):4656-62. PubMed ID: 11739384
[TBL] [Abstract][Full Text] [Related]
38. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
Kim W; Kaelin WG
Curr Opin Genet Dev; 2003 Feb; 13(1):55-60. PubMed ID: 12573436
[TBL] [Abstract][Full Text] [Related]
39. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
40. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
Pioli PA; Rigby WF
J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
